Altfest L J & Co. Inc. Cuts Stake in Eli Lilly and Company (NYSE:LLY)

Altfest L J & Co. Inc. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 7,910 shares of the company’s stock after selling 317 shares during the quarter. Altfest L J & Co. Inc.’s holdings in Eli Lilly and Company were worth $4,611,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Procyon Advisors LLC lifted its stake in Eli Lilly and Company by 15.5% during the 4th quarter. Procyon Advisors LLC now owns 3,824 shares of the company’s stock valued at $2,229,000 after acquiring an additional 514 shares during the period. Parisi Gray Wealth Management lifted its stake in Eli Lilly and Company by 58.9% during the 4th quarter. Parisi Gray Wealth Management now owns 5,423 shares of the company’s stock valued at $3,161,000 after acquiring an additional 2,010 shares during the period. Planned Solutions Inc. bought a new position in Eli Lilly and Company during the 4th quarter valued at about $1,997,000. S.A. Mason LLC lifted its stake in Eli Lilly and Company by 2.0% during the 4th quarter. S.A. Mason LLC now owns 1,786 shares of the company’s stock valued at $1,041,000 after acquiring an additional 35 shares during the period. Finally, Highland Capital Management LLC lifted its stake in Eli Lilly and Company by 2.8% during the 4th quarter. Highland Capital Management LLC now owns 13,350 shares of the company’s stock valued at $7,782,000 after acquiring an additional 360 shares during the period. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 1,180 shares of the firm’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $645.60, for a total value of $761,808.00. Following the completion of the transaction, the insider now directly owns 99,542,630 shares of the company’s stock, valued at $64,264,721,928. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders sold a total of 195,055 shares of company stock valued at $125,254,657 in the last three months. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

LLY traded up $0.84 during trading on Wednesday, reaching $775.74. 1,002,283 shares of the company traded hands, compared to its average volume of 3,214,925. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 12-month low of $334.58 and a 12-month high of $800.78. The firm has a fifty day simple moving average of $725.15 and a 200 day simple moving average of $634.68. The company has a market cap of $737.08 billion, a P/E ratio of 133.55, a PEG ratio of 1.70 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the firm posted $2.09 EPS. The company’s revenue was up 28.1% on a year-over-year basis. On average, equities analysts forecast that Eli Lilly and Company will post 12.42 EPS for the current year.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $689.52.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.